Biotechnology News

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced the presentation of preclinical proof-of-concept data and new clinical...

In a Phase 1/1b clinical trial, WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the outpatient setting as monotherapy and in combination with pembrolizumab, with...

SAB05 blocked CD40 signaling and delivered its glucocorticoid payload selectively into CD40-positive immune cells in vitroIn a mouse arthritis model, a surrogate of SAB05 at higher doses matched the...

SANTA ANA, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and...

Tevogen secures two extra years of capital access, with up to $28.6 million in borrowing capacity through May 2029, complementing its existing ATM program.

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced that...

If approved, cebranopadol would be the first dual NOP/MOP receptor (dual-NMR) agonist analgesic available for moderate-to-severe acute pain, introducing a novel mechanism of action to a treatment...

WATERTOWN, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of...

New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient responses to bezisterim treatment. Patients with a...

– Humacyte has initiated the CABG clinical study and looks forward to the commencement of screening for potential patients.  – “Moving it into a first-in-human study is the step that will tell us...